Cargando…

Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats

BACKGROUND: The most frequent pain in patients with metastatic breast and prostate cancer is bone pain, which can be severe and difficult to treat. The mechanisms underlying this pain remain unclear. Here we investigated the role of c-jun N-terminal kinase (JNK) pathway in the spinal cord in cancer-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao-Wei, Hu, Shan, Mao-Ying, Qi-Liang, Li, Qian, Yang, Chang-Jiang, Zhang, Hui, Mi, Wen-Li, Wu, Gen-Cheng, Wang, Yan-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407760/
https://www.ncbi.nlm.nih.gov/pubmed/22681856
http://dx.doi.org/10.1186/1756-6606-5-21
Descripción
Sumario:BACKGROUND: The most frequent pain in patients with metastatic breast and prostate cancer is bone pain, which can be severe and difficult to treat. The mechanisms underlying this pain remain unclear. Here we investigated the role of c-jun N-terminal kinase (JNK) pathway in the spinal cord in cancer-induced bone pain (CIBP). RESULTS: In this study, we used an established rat CIBP model to investigate the possible role of JNK activation in the spinal cord. After intra-tibial inoculation with Walker 256 rat mammary gland carcinoma cells, the rats displayed mechanical allodynia on day 5, which lasted to day 16. The activation of JNK in neurons and astrocytes in the spinal cord was found on day 12 and day 16 after intra-tibial inoculation with carcinoma cells. A single intrathecal injection with JNK inhibitor SP600125 by lumbar puncture attenuated mechanical allodynia on day 12, and repeated intrathecal injection of SP600126 from day 10 to day 14 had a cumulative analgesic effect on CIBP. CONCLUSIONS: Taken together, our results demonstrated for the first time that JNK activation in the spinal cord is required in the maintenance of CIBP. Inhibition of the spinal JNK pathway may provide a new therapy for CIBP management.